# Which option fits what you want to do? *Options by Goal | regenerative medicine phoenix* > regenerative medicine phoenix options for a sore joint, from home care and physical therapy to non-surgical care or a surgery talk. ## Do I want less soreness or a rebuilt joint? Phoenix already gives you plenty of driving. Don't add clinic trips until you know what you want back. Maybe it's walking through a store, climbing steps, sleeping, or lifting your arm. Less soreness is a fair goal. Easier movement is another. Rebuilding a worn joint surface is different. Non-surgical care hasn't been shown to do that. Once your goal is clear, you can weigh the money, time, and work. Choose by the daily task you want back, not a fancy name. ## What can help me move more easily? Start with care that fits your joint. Physical therapy can strengthen the muscles and teach safer movement. A brace or cane may ease the load on a hip or knee. Heat, cold, and medicine can help you stay active when they're safe for you. This takes steady work. That's the catch. If an exercise causes sharp soreness or leaves you worse tomorrow, ask for a change. You won't earn anything by forcing it. Break chores into smaller parts and rest before the joint flares. Regular, manageable work beats one hard day. ## What are orthobiologics? Orthobiologics is a clinic word for shots made with blood or bone marrow. The letters PRP mean platelet-rich plasma. Staff take a blood draw, spin it so platelets gather, and put the liquid in the aching joint. Concentrated PRP has more platelets in the liquid. Bone marrow aspirate concentrate is different. Here, aspirate means marrow drawn from the pelvis. Staff spin that marrow to gather its cells, then place the liquid into the joint. Studies on these shots have mixed results, and prices vary, so get the full amount in writing before deciding whether either choice is worth the money and return visits. The exam, joint wear, and evidence for that joint help guide the choice. Cartilage regeneration isn't a fair promise for a joint worn in many places. If you ask can cartilage regenerate, separate feeling better from rebuilding the joint. A shot may aim to ease soreness, but it hasn't been shown to rebuild a broadly worn surface. The main difference is whether staff prepare blood or marrow before the shot. ## What can QC Kinetix discuss with me? Joint preservation isn't a separate shot. It means trying to keep the natural joint while weighing non-surgical care and the timing of knee or hip surgery. Ask which shot matches the exam and why. You also need the full price, the likely return visits, and the work expected afterward. Don't agree until those answers make sense. At a QC Kinetix visit, medical providers, meaning the staff who examine you, may offer shots made from blood or marrow as regenerative treatments and biologic therapies. ## Sources 1. The AAOS third-edition clinical practice guideline for non-arthroplasty management of knee osteoarthritis is the orthopedic profession's own GRADE-style appraisal of the same options a regenerative clinic sells; it is the benchmark against which any 'regenerative' claim on this topic should be read, and it rates the strongest support for exercise, weight loss and self-management rather than for injectables. Brophy RH, et al. — [AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Nonarthroplasty), Third Edition.](https://pubmed.ncbi.nlm.nih.gov/35383651/). *The Journal of the American Academy of Orthopaedic Surgeons*, 2022. DOI: 10.5435/JAAOS-D-21-01233. 2. The RESTORE trial - a participant-, injector- and assessor-blinded RCT of 288 adults aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence 2-3) - compared three weekly intra-articular PRP injections against saline placebo, with co-primary endpoints of 12-month knee pain and medial tibial cartilage volume on MRI. PRP did not beat placebo on either. It is the single best-designed test of the specific claim that PRP changes joint structure, and it was negative. Bennell KL, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 3. A four-arm, multicentre, single-blind phase 2/3 randomized trial of 480 knee OA patients (KL II-IV) compared autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction and allogeneic umbilical-cord-tissue mesenchymal stromal cells against a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another, or to the corticosteroid control, and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events occurred. Mautner K, et al. — [Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.](https://pubmed.ncbi.nlm.nih.gov/37919438/). *Nature medicine*, 2023. DOI: 10.1038/s41591-023-02632-w. 4. A 2026 systematic review and meta-analysis of 28 randomized trials of intra-articular mesenchymal stem cell-based therapies in knee OA found significant improvements in several pain and function measures (delta-VAS MD -1.67; KOOS pain MD 15.37) but NO significant difference in WOMAC, KOOS quality of life or the Lequesne index, and MRI-based WORMS scores were non-significant - indicating no consistent structural benefit. Its own conclusion: these therapies serve a primarily SYMPTOM-modifying rather than STRUCTURE-modifying role, with higher frequencies of local reactions to weigh against the symptomatic benefit. Awad G, et al. — [Efficacy and safety of intra-articular mesenchymal stem cell-based therapies in knee osteoarthritis: A systematic review and meta-analysis of randomized controlled trials.](https://pubmed.ncbi.nlm.nih.gov/41863718/). *Clinical rheumatology*, 2026. DOI: 10.1007/s10067-026-08042-w. 5. MACI (autologous cultured chondrocytes on a porcine collagen membrane, Vericel; STN BL 125603) IS an FDA-LICENSED cell therapy - and its approved indication is narrow and specific: repair of symptomatic, single or multiple FULL-THICKNESS cartilage defects OF THE KNEE, with or without bone involvement, in adults. It is not approved for osteoarthritis. The existence of one licensed cartilage cell therapy for focal defects is the sharpest available way to show what a licensed 'regeneration' product actually looks like, and how far it is from an injection for a worn joint. US Food and Drug Administration, Center for Biologics Evaluation and Research — [MACI (autologous cultured chondrocytes on porcine collagen membrane)](https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/maci-autologous-cultured-chondrocytes-porcine-collagen-membrane). *FDA*, 2024. 6. The SUMMIT randomized trial treated 144 patients (mean age 33.8, mean lesion 4.8 cm2) with at least one symptomatic focal cartilage defect (Outerbridge III/IV, >=3 cm2) of the femoral condyle or trochlea. Matrix-applied characterized autologous cultured chondrocytes (MACI) improved KOOS pain (37.0 to 82.5) and function significantly more than microfracture (pain 35.5 to 70.9) at 2 years, with histological and MRI assessment of the repair tissue. This is what a positive cartilage-repair trial looks like - in young patients with a discrete hole, not a worn joint. Saris D, et al. — [Matrix-Applied Characterized Autologous Cultured Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective Randomized Trial.](https://pubmed.ncbi.nlm.nih.gov/24714783/). *The American journal of sports medicine*, 2014. DOI: 10.1177/0363546514528093. 7. FORWARD, the longest disease-modifying osteoarthritis drug trial reported to date, gave intra-articular sprifermin (a recombinant FGF-18) or placebo to knee OA patients and followed 378 of them for 5 years. Sprifermin produced a significant, sustained dose-response INCREASE in total femorotibial cartilage thickness versus placebo - and WOMAC pain improved about 50% from baseline in ALL groups, including placebo. It is the cleanest demonstration in the literature that adding measurable cartilage and relieving pain are two different results, and that one does not deliver the other. Eckstein F, et al. — [Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study.](https://pubmed.ncbi.nlm.nih.gov/33962962/). *Annals of the rheumatic diseases*, 2021. DOI: 10.1136/annrheumdis-2020-219181. 8. A GRADE-rated systematic review and meta-analysis of 16 randomized trials (807 participants) found that MSC therapy for chronic knee OA pain PROBABLY RESULTS IN LITTLE TO NO DIFFERENCE in pain relief at 3-6 months (WMD -0.74 cm on a 10 cm VAS against a minimally important difference of 1.5 cm) or physical functioning (WMD 2.23 on the SF-36 100-point subscale against a 10-point MID), both moderate certainty; at 12 months pain was again probably little-to-no-different (WMD -0.73 cm). The measured effect is real but sits BELOW the threshold at which a patient would notice it. Sadeghirad B, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 9. A randomized, double-blind, placebo-controlled trial in a Japanese population tested leukocyte-POOR PRP specifically in mild-to-moderate knee OA WITH joint effusion or bone marrow lesions - i.e. a selected inflammatory phenotype rather than all comers. Recorded here because phenotype selection, not the product, is the most plausible explanation for why PRP trials disagree with one another. Yoshioka T, et al. — [The Effectiveness of Leukocyte-Poor Platelet-Rich Plasma Injections for Symptomatic Mild to Moderate Osteoarthritis of the Knee With Joint Effusion or Bone Marrow Lesions in a Japanese Population: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/39097760/). *The American journal of sports medicine*, 2024. DOI: 10.1177/03635465241263073. 10. A CDC-led national public health investigation identified culture-confirmed bacterial infections in 20 patients (median age 63) across 8 US states who received umbilical cord blood-derived products marketed as stem cell treatment for pain, osteoarthritis, rheumatoid arthritis and injury. ALL BUT ONE REQUIRED HOSPITALISATION. Of unopened, undistributed product vials sampled, 65% (22 of 34) were contaminated with at least one of 16 bacterial species, mostly enteric; whole-genome sequencing linked an Arizona patient isolate to product administered in Florida. Hartnett KP, et al. — [Investigation of Bacterial Infections Among Patients Treated With Umbilical Cord Blood-Derived Products Marketed as Stem Cell Therapies.](https://pubmed.ncbi.nlm.nih.gov/34618037/). *JAMA network open*, 2021. DOI: 10.1001/jamanetworkopen.2021.28615. ## Want the joint looked at? Phoenix-area QC Kinetix clinics offer consultations. Their medical providers, the staff who examine your joint, can discuss non-surgical shots prepared from blood or bone marrow. Choose Banner Estrella, Scottsdale, Chandler, or Peoria based on your drive. One number reaches the team: (602) 837-PAIN. Bring your X-ray if you have one. Be ready to name the daily task you want back. Book a free consultation: --- Clear answers for a joint that still hurts. Direct help with joint soreness, simple home steps, signs that need care and regenerative medicine phoenix options from QC Kinetix. Direct Phoenix guidance on joint soreness, simple home steps, warning signs and non-surgical options. This site is operated by the owners of the QC Kinetix Phoenix-area clinics — Banner Estrella, Scottsdale, Peoria and Chandler — and those owners may benefit when a reader books a consultation. © 2026 Phoenix Joint Decision. General education only, not personal medical advice; urgent warning signs require appropriate medical assessment.